Discontinued — last reported Q3 '25
Biogen Deferred Tax Assets decreased by 4.7% to $483.50M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 263.0%, from $133.20M to $483.50M. Over 4 years (FY 2021 to FY 2025), Deferred Tax Assets shows a downward trend with a -13.3% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase can signal future tax efficiency or the utilization of past losses, while a decrease may indicate the realization of those benefits.
These are assets on the balance sheet that represent future tax savings resulting from temporary differences between the...
Common in large, capital-intensive companies; peers with significant R&D spending often have large deferred tax assets from tax credits.
deferred_tax_assets| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $490.00M | $490.00M | $31.70M | $1.00M | -$48.50M | -$92.30M | $37.20M | $251.30M | $143.90M | $728.10M | $641.80M | $658.10M | $590.60M | $882.40M | $190.50M | $133.20M | $118.30M | $358.10M | $507.60M | $483.50M |
| QoQ Change | — | +0.0% | -93.5% | -96.8% | <-999% | -90.3% | +140.3% | +575.5% | -42.7% | +406.0% | -11.9% | +2.5% | -10.3% | +49.4% | -78.4% | -30.1% | -11.2% | +202.7% | +41.7% | -4.7% |
| YoY Change | — | — | — | — | -109.9% | -118.8% | +17.4% | >999% | +396.7% | +888.8% | >999% | +161.9% | +310.4% | +21.2% | -70.3% | -79.8% | -80.0% | -59.4% | +166.5% | +263.0% |